Tofacitinib FAQs
← back to Tofacitinib
5 questions
FAQs
- What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata? Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
- How does tofacitinib differ when used orally versus topically in hair loss treatment research? Oral tofacitinib acts on immune signalling throughout the body and has more published regrowth data in alopecia areata (from small studies without placebo groups), alongside an FDA boxed warning; topical tofacitinib aims to act only on the scalp, but the human evidence is a handful of small compounded-formulation studies with no large randomized trial. Neither route is approved for hair loss, and regrowth generally reverses after treatment stops.
- Why is tofacitinib considered a medical treatment rather than a cosmetic or preventative hair product? Tofacitinib is a prescription JAK inhibitor regulated as a drug, with an FDA boxed warning; its use for alopecia areata is off-label. Studies report regrowth while it is taken, which usually reverses after stopping, so it treats disease activity rather than acting as a cosmetic.
- What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.
- What are the key limitations and considerations surrounding tofacitinib in hair loss products and therapies? Reported hair regrowth with tofacitinib comes from alopecia areata, an autoimmune condition — mostly from small, non-randomized studies, with relapse common after stopping. There is no good evidence it helps pattern hair loss, and it is not approved for hair loss anywhere.